Document Detail


Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy.
MedLine Citation:
PMID:  16865285     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Based on the finding that telomerase is reactivated solely in cancer cells, the human telomerase reverse transcriptase (hTERT) promoter has recently been used to target cancer cells by gene therapy. The recent, surprising observation that telomerase is physiologically activated even in normal somatic cells during S-phase has raised concerns as to the safety of this methodology. To clarify this issue, the present study carefully examined the changes in endogenous telomerase activities, hTERT mRNA expression, and hTERT promoter-based transgene expression in normal and cancer cells at synchronized phases of the cell cycle. Telomerase activity and hTERT expression were detected at variable, but relatively high, levels in all 12 cancer cell lines, while both were undetectable in the 11 normal cell lines. In HepG2 cancer cells, the highest levels of hTERT expression and telomerase activity, seen in the G(1)/S- and S-phases, were 2-3-fold higher than the lowest levels of both, observed in G(0)-phase and during asynchronization. No hTERT expression or telomerase activitiy could be detected in normal WI-38 fibroblasts at any phase of the cell cycle, including S-phase. Consequently, activity of the shorter hTERT promoter, which was transferred into HepG2 cancer cells via adenovirus transduction, was stronger than that of the longer hTERT promoter at all phases and that of two representatives of ubiquitously strong promoters, at both S-phase and asynchronization, but not at G(0)-phase. In contrast, neither of hTERT promoters induced detectable transgene expressions in normal WI-38 cells at any cell cycle phase, including S-phase. These results, particularly the lack of problematic levels of S-phase-specific activation of hTERT promoters in normal cells, have promising implications for hTERT promoter-based targeted gene therapy of cancer.
Authors:
Yoshiteru Murofushi; Satoshi Nagano; Junichi Kamizono; Tomoyuki Takahashi; Hisayoshi Fujiwara; Setsuro Komiya; Toyojiro Matsuishi; Ken-ichiro Kosai
Related Documents :
20028875 - Dna damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant ...
25325055 - Impact of amorphous sio2 nanoparticles on a living organism: morphological, behavioral,...
12114965 - Telomere shortening of mcf-7 cells caused by antisense telomerase cdna.
16131355 - Telomere biology in aging and cancer.
2790485 - Potassium conductance block by barium in amphibian müller cells.
3002825 - Interaction of camp with the cdc25-mediated step in the cell cycle of budding yeast.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of oncology     Volume:  29     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-07-25     Completed Date:  2006-10-05     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  681-8     Citation Subset:  IM    
Affiliation:
Division of Gene Therapy and Regenerative Medicine, Cognitive and Molecular Research Institute of Brain Diseases, Kurume University, Kurume 830-0011, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenoviridae / genetics*
Bone Neoplasms / enzymology,  genetics,  therapy
Carcinoma, Hepatocellular / enzymology,  genetics,  therapy
Catalytic Domain
Colonic Neoplasms / enzymology,  genetics,  therapy
DNA-Binding Proteins / genetics*,  metabolism
G0 Phase
Gene Targeting*
Gene Therapy*
Genetic Vectors
Humans
Liver Neoplasms / enzymology,  genetics,  therapy
Neoplasms / enzymology,  genetics*,  therapy
Osteosarcoma / enzymology,  genetics,  therapy
Promoter Regions, Genetic / genetics*
RNA, Messenger / genetics,  metabolism
S Phase*
Telomerase / genetics*,  metabolism
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/DNA-Binding Proteins; 0/RNA, Messenger; EC 2.7.7.49/Telomerase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gene expression profile of DNA binding protein A transgenic mice.
Next Document:  Participation of nuclear localization signal 2 in the 3'-ETS domain of FLI1 in nuclear translocation...